Oppenheimer & Co. Inc. Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Oppenheimer & Co. Inc. acquired a new stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,253 shares of the company's stock, valued at approximately $232,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of SLNO. Janus Henderson Group PLC grew its holdings in Soleno Therapeutics by 27.1% during the fourth quarter. Janus Henderson Group PLC now owns 5,188,265 shares of the company's stock worth $233,130,000 after buying an additional 1,107,166 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in Soleno Therapeutics by 20.1% during the fourth quarter. Nantahala Capital Management LLC now owns 3,928,966 shares of the company's stock worth $176,607,000 after buying an additional 658,518 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in Soleno Therapeutics during the first quarter worth $31,046,000. Avoro Capital Advisors LLC grew its holdings in Soleno Therapeutics by 15.8% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,525,000 shares of the company's stock worth $113,499,000 after buying an additional 344,000 shares in the last quarter. Finally, Vestal Point Capital LP grew its holdings in Soleno Therapeutics by 47.2% during the fourth quarter. Vestal Point Capital LP now owns 1,060,000 shares of the company's stock worth $47,647,000 after buying an additional 340,000 shares in the last quarter. Institutional investors own 97.42% of the company's stock.

Soleno Therapeutics Stock Up 0.5%

SLNO stock opened at $86.64 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 19.64 and a current ratio of 19.64. The company has a market capitalization of $4.37 billion, a price-to-earnings ratio of -18.75 and a beta of -2.63. Soleno Therapeutics, Inc. has a fifty-two week low of $40.19 and a fifty-two week high of $87.16. The stock has a fifty day moving average of $77.64 and a 200-day moving average of $61.05.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.95) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.19. As a group, equities research analysts predict that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on SLNO. TD Cowen began coverage on Soleno Therapeutics in a report on Monday, June 23rd. They set a "buy" rating and a $110.00 price target for the company. Robert W. Baird upped their price target on Soleno Therapeutics from $102.00 to $105.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Stifel Nicolaus boosted their price objective on Soleno Therapeutics from $74.00 to $108.00 and gave the stock a "buy" rating in a research report on Friday, March 28th. Cowen assumed coverage on Soleno Therapeutics in a research report on Monday, June 23rd. They issued a "buy" rating on the stock. Finally, UBS Group set a $105.00 price objective on Soleno Therapeutics in a research report on Thursday, March 27th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $107.10.

Insider Buying and Selling at Soleno Therapeutics

In other news, insider Patricia C. Hirano sold 3,830 shares of the stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $82.76, for a total transaction of $316,970.80. Following the completion of the transaction, the insider owned 13,206 shares in the company, valued at approximately $1,092,928.56. This represents a 22.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 6.40% of the company's stock.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.

Want to see what other hedge funds are holding SLNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.